Capital Markets & Financing
Schroders Capital to expand private equity operations in China
Schroders Capital is close to launching its first onshore private equity offering in China, as it looks to capitalise on the growing renminbi market.
Diamond Equity Research Initiates Coverage on YS Biopharma Co., Ltd. (NASDAQ: YS)
Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of YS Biopharma Co., Ltd. (NASDAQ: YS).
Novo Holdings participates in $290m strategic financing of Sangon Biotech
Novo Holdings, a leading international life science investor, today announced it has participated in a $290 million (USD) strategic financing round of Sangon Biotech.
Japanese and Chinese Healthcare Companies Dominate in Asian Capital Market
A review of the top 25 Healthcare companies in Asia-Pacific
Neurophth Secures Nearly 95 Million USD in Series C+ Financing for Gene Therapy Clinical Trials
Neurophth Therapeutics, Inc. ("Neurophth"), a China's leading gene therapy company for ophthalmic diseases, announced the closing of nearly 95 million USD in Series C+ financing.
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
Gracell Biotechnologies Inc. ("Gracell" or the "Company", Nasdaq: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it has entered into a purchase agreement with a select group of institutional and accredited healthcare specialist investors for the private placement of (i) 138,900,000 ordinary shares of the Company (the "Ordinary Shares") (equivalent to 27,780,000 of the Company's American depositary shares ("ADSs")), at a purchase price equivalent to $3.60 per ADS, and (ii) warrants to purchase up to 44,802,870 Ordinary Shares (equivalent to 8,960,574 ADSs) (the "Warrants") at an exercise price equivalent to $5.58 per ADS, representing a 55% premium to the purchase price of Ordinary Shares.
Hong Kong-based biotech Insilico Medicine shifts IPO plan to city from New York
Hong Kong-based biotech company Insilico Medicine has set its sights on an initial public offering in the city, shelving its earlier New York fundraising plan, as the start-up seeks capital to finance clinical trials of drugs discovered and designed by artificial intelligence.
Qiming-Backed AI Drug Discovery Startup Insilico Medicine Files For Hong Kong IPO
Insilico Medicine, a Hong Kong and New York-based company that uses AI for drug discovery, has filed for an initial public offering in the Asian financial hub that’s slowly recovering from a drought of major listings.
Hong Kong removes requirement to flag China risk in listing applications
Hong Kong stock exchange has removed a China-risk section for mainland-incorporated companies in its listing application rules with effect from Tuesday, which the bourse said was to align disclosure requirements for IPO-aspirants from other countries and the scrutiny level remains the same.
Biden order proposes new restrictions on China tech investment
President Biden signed an executive order Wednesday aimed at curbing the flow of U.S. investment and management know-how into a limited range of Chinese firms that the administration fears could fuel Beijing’s military ambitions.
